The role of antimalarials in the exacerbation of psoriasis: A systematic review

American Journal of Clinical Dermatology

Volumn 7, Issue 4, 2006, Pages 249-257

  Herman, Sari M ^a   Shin, Michael H ^a   Holbrook, Anne ^a,b   Rosenthal, Donald ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b CENTRE FOR EVALUATION OF MEDICINES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ANTIMALARIAL AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLOROQUINE; CHLORPHENIRAMINE; CORTICOSTEROID; HYDROXYCHLOROQUINE; INTERFERON; LITHIUM; MEPACRINE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; PRIMAQUINE; PROGUANIL; PSORALEN DERIVATIVE; QUINIDINE; QUININE; TAR; TETRACYCLINE DERIVATIVE;

ARTICLE; CLINICAL TRIAL; DISEASE EXACERBATION; ERYTHRODERMA; HUMAN; MALARIA; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RHEUMATIC DISEASE; SYSTEMATIC REVIEW;

ANTIMALARIALS; HUMANS; META-ANALYSIS; META-ANALYSIS AS TOPIC; PSORIASIS;

EID: 33747256273     PISSN: 11750561     EISSN: 11750561     Source Type: Journal    
DOI: 10.2165/00128071-200607040-00006     Document Type: Article

References (49)

1. Lebwohl M. Psoriasis. Lancet 2003; 361: 1197-204
2. Veale DJ, FitzGerald O. Psoriatic arthritis-pathogenesis and epidemiology. Clin Exp Rheumatol 2002; 20 (6 Suppl. 28): S27-33
3. Kaipiainen-Seppanen O. Incidence of psoriatic arthritis in Finland. Br J Rheumatol 1996; 35: 1289-91
4. Habif TP. Clinical dermatology [e-book; online]. Philadelphia (PA): Mosby, 2004. Available from URL: http://www.mdconsult.com/ [Accessed 2005 May 30]
5. Ashcroft DM, Wan Po AL, Williams HC, et al. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 1999; 141: 185-91
6. Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44
7. Abel E, Di Cicco L, Orenberg E, et al. Drugs in exacerbation of psoriasis. J Am Acad Dermatol 1986; 15: 1007-22
8. Tsankov N, Kazandjieva J, Drenovska K. Drugs in exacerbation and provocation of psoriasis. Clin Dermatol 1998; 16: 333-51
9. Tsankov N, Angelova I, Kazandijieva J. Drug-induced psoriasis: recognition and management. Am J Clin Dermatol 2000; 1: 159-65
10. Guenther LC, Ortonne JP. Pathophysiology of psoriasis: science behind therapy. J Cutan Med Surg 2002; 6: 2-7
11. Olsen TG. Chloroquine and psoriasis. Ann Intern Med 1981; 94: 546-7
12. Vestey FP, Savin FA. Psoriasis worsened by antimalarial prophylaxis. J Infect 1992; 24: 211-21
13. Brenner S, Cabili S, Wolf R. Widespread erythematous scaly plaques in an adult. Arch Dermatol 1993; 129: 1331-5
14. MacKenzie AH, Scherbel AL. Chloroquine and hydroxychloroquine. Clin Rheum Dis 1980; 7: 545-66
15. Mallett R, Pye R. Risks and benefits of prophylactic antimalarial drugs [letter]. BMJ 1989; 299: 1400
16. Gladman DD, Blake R, Brubacher B, et al. Chloroquine therapy in psoriatic arthritis. J Rheumatol 1992; 19: 1724-6
17. Kuflik EG. Effect of antimalarial drugs on psoriasis. Cutis 1980; 26: 153-6
18. Cornbleet T. Preliminary and short report: action of synthetic antimalarial drugs on psoriasis. J Invest Dermatol 1956; 26: 435-6
19. Luzar MJ. Hydroxychloroquine in psoriatic arthropathy. J Rheumatol 1982; 9: 462-4
20. Slagel GA, James WD. Plaquenil induced erythroderma. J Am Acad Dermatol 1985; 12: 857-62
21. Knudsen EA. Exfoliative erythroderma due to chloroquine: psoriasis [abstract]. Acta Derm Venereol (Stockh) 1962; 42: 344
22. Granirer LW. Exfoliative dermatitis as a complication of chloroquine (Aralen) therapy in rheumatoid arthritis. AMA Arch Derm 1958; 77: 722-4
23. Reed WB, Becker SW. Psoriasis and arthritis. Arch Dermatol 1960; 81: 577-85
24. Witten VH, Sulzberger MB. Psoriasis: an interesting and perhaps distinctive response following quinacrine therapy. Arch Dermatol 1956; 73: 636
25. Witten VH, Sultzberger MC. Psoriasis: an unusual response following atabrine. Arch Dermatol 1956; 74: 210-1
26. Kammer GM, Sotar NA, Gibson DJ. Psoriatic arthritis: a clinical, immunologic, and HLA study of 100 patients. Semin Arthritis Rheum 1979; 9: 75-95
27. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Arthritis Rheum 1990; 33: 1449-61
28. Gabriel SE, Coyle D, Moreland LW. A clinical and economic review of disease-modifying antirheumatic drugs. Pharmacoeconomics 2001; 19: 715-28
29. Sackett DL. Rules of evidence and clinical recommendations on the use of antithrombotic agents. Chest 1989; 95 Suppl. 2: 2S-4S
30. Baker H. The influence of chloroquine and related drugs on psoriasis and keratoderma blenorrhagicum. Br J Dermatol 1966; 78: 161-6
31. Bielicky T. Light-sensitive psoriasis and antimalarial drugs. J Invest Dermatol 1963; 41: 1-2
32. Bielicky T, Malina L, Sonka J. Glucose metabolism and clinical alterations in psoriasis under chloroquine therapy. Acta Derm Venereol (Stockh) 1966; 46: 72-7
33. Cormia FE, Noun MH. Treatment of pustular psoriasis and pustular bacterid with quinacrine (Atabrine). AMA Arch Derm Syphilol 1953; 68: 337-8
34. Friedman SS. Pustular psoriasis associated with hydroxy chloroquine. J Am Acad Dermatol 1987; 16: 1256-7
35. Gordon MM, Sturrock RD. Antimalarials in the management of psoriatic arthritis? [letter]. Clin Exp Rheumatol 2002; 20: 117
36. Gray RG. Hydroxychloroquine provocation of psoriasis [letter]. J Rheumatol 1985; 12: 391
37. Harwell WB. Quinidine-induced psoriasis [letter]. J Am Acad Dermatol 1983; 9: 278
38. Hays S, Camisa C, Luzar MJ. The coexistence of systemic lupus erythematous and psoriasis. J Am Acad Dermatol 1984; 10: 619-22
39. Katugampola G, Katugampola S. Chloroquine and psoriasis. Int J Dermatol 1990; 29: 153-4
40. Kirschenbaum MC. Psoriasis following administration of antimalarial drugs. JAMA 1963; 185: 1044
41. Luzar MJ, Camisa C. Antimalarials in psoriatic arthritis [letter]. J Rheumatol 1983; 10: 833-4
42. O'Quinn S, Kennedy CB, Naylor LZ. Psoriasis, ultraviolet, and chloroquine. Arch Dermatol 1964; 90: 211-6
43. Potasman I, Seligmann H. A unique case of mefloquine-induced psoriasis [letter]. J Travel Med 1998; 5: 156
44. Reed WB. Psoriatic arthritis: a complete clinical study of 86 patients. Acta Derm Venereol (Stockh) 1961; 41: 396-403
45. Roberts MET, Wright V, Hill AGS, et al. Psoriatic arthritis. Ann Rheum Dis 1976; 35: 203-12
46. Sayers ME. Use of antimalarial drugs for the treatment of psoriatic arthritis. Am J Med 1992; 93: 474-5
47. Trnavsky K, Zbojanova M, Vlcek F. Antimalarials in psoriatic arthritis [letter]. J Rheumatol 1983; 10: 833-4
48. Levine M, Haslam D, Walter S, et al. Harm. In: Guyatt G, Rennie D, editors. Users' guide to the medical literature. Chicago: American Medical Association, 2002: 121-153
49. Abel EA. Diagnosis of drug-induced psoriasis. Semin Dermatol 1992; 11: 269-74